The Efficacy of Nutrilite All-plant Protein Booster to Improve Sarcopenia and Osteoarthritis in Middle-aged and Elderly People

A Randomized, Double-blind Clinical Study of the Efficacy of Nutrilite All-plant Protein Booster to Improve Sarcopenia and Osteoarthritis in Middle-aged and Elderly People

The goal of this clinical trial is to learn whether Amway Nutrilite All-plant protein booster prototype product (test product) will improve sarcopenia (SA) and osteoarthritis (OA) in middle-aged and elderly people. It will also learn about the improvement of Quality of life (QoL) in them. The main questions it aims to answer are:

• Does the test product will improve the SA in terms of Short Physical Performance Battery (SPPB score) after 12 weeks' intervention?
• Does the test product will improve the OA in terms of Western Ontario and McMaster Universities Arthritis (WOMAC Index) after 12 weeks' intervention?

Researchers will compare Amway All-plant protein booster prototype product to a placebo (a look-alike substance that contains no similar active nutrient ingredients) to see if the test product works to improve SA and OA.

Participants will:

• Take the test product or a placebo 2 spoons (15g) twice per day for 12 weeks
• Visit the site on the baseline day and the 84th day (end day of 12 weeks) for checkups and tests

Study Overview

• Status: Completed
• Conditions: Osteoarthritis; Sarcopenia
• Intervention / Treatment: Dietary supplement: All-plant Protein Booster Product Group; Dietary supplement: Placebo Group

• Study Type: Interventional
• Enrollment (Actual): 139
• Phase: Not Applicable

Contacts and Locations

Study Locations

• China
  • Zhejiang
    • Jinhua, Zhejiang, China
      • Jinhua Wenrong Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Be age 50 to 70 years, female and male
• Participants will be required to have mild to moderately OA & SA evaluated by Kellgren-Lawrence I-II and SARC-Cal, respectively
• Participants need to be competent i.e., able to understand what is to take place and able to provide a free decision on agreeing to the activity/taking part on the study on this
• Participants must be able to read and understand study instructions and any other relevant study documents
• Willing to following the lifestyle restrictions as detailed in the Information Sheet for study
• Will to give written informed consent

Exclusion Criteria:

• Have a fever currently, or for 24 hours before enrollment
• Currently participating in another clinical study
• Have taken other protein powder products and dietary supplements or medicines containing peptides or hyaluronic acid within the past 6 months (subject to product instructions)
• Individuals receiving medical treatment that, in the opinion of the Principal Investigator or Study Physician, may interfere with test results
• The participant is an employee of Amway or SPRIM Medical
• Subject who is in the treatment of gastrointestinal diseases
• Subject with abnormal liver function tests (alanine aminotransferase and aspartate aminotransferase), kidney function tests (blood urea nitrogen and creatinine), blood routine, urine routine, fecal occult blood test, or electrocardiogram.
• Subjects have any of the following medical history or have been clinically examined to have the following diseases that may affect the evaluation of the test effect: obvious gastrointestinal dysfunction, liver, kidney, endocrine, blood, respiratory and cardiovascular diseases

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: All-plant Protein Booster Product Group; Containing ingredients: Soy protein Isolate, Soybean peptide, wheat protein, pea protein, Pea peptide, Aloe Vera powder, Sweetener (Maltitol) Anti-caking (Silicon Dioxide) Thickener (guar gum, arabic gum)	Dietary supplement: All-plant Protein Booster Product Group; Participants in this arm will take 2 spoons (15g) twice per day for 12 weeks
Placebo Comparator: Placebo Group; Containing ingredients: Aloe Vera powder, Sweetener (Maltitol) Anti-caking (Silicon Dioxide) Thickener (guar gum, arabic gum)	Dietary supplement: Placebo Group; Participants in this arm will take 2 spoons (15g) twice per day for 12 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of SPPB Score from baseline	The SPPB (Short Physical Performance Battery) test is a group of measures that combines the results of the gait speed, chair stand and balance tests (Guralnik et al., 2000). lt has been used as a predictive tool for possible disability and can aid in the monitoring of function in older people. The scores range from 0 (worst performance) to 12 (best performance).	baseline day 0, week 12
Change of WOMAC 3.1 index from baseline	The WOMAC (Western Ontario and McMaster Universities Arthritis) Index was created to assess pain, stiffness, and physical function in patients with hip and / or knee osteoarthritis (OA). The WOMAC 3.1 consists of 24 items divided into 3 subscales. The scores are summed for items in each subscale, with possible ranges as follows: pain=0-20, stiffness=0-8, physical function=0-68. A total WOMAC score is created by summing the items for all three subscales. (0-96), higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.	baseline day 0, week 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of bone density measured by DXA Bone Densitometer from baseline	Change of bone density measured by DXA Bone Densitometer from baseline to week 12	baseline day 0, week 12
Improvement of Fat and Muscle Portions measured by Inbody S10 from baseline	Improvement of Fat and Muscle Portions measured by Inbody S10 from baseline to week 12	baseline day 0, week 12
Improvement of Quality of Life by WHOQOL BREF	WHOQOL-BREF is a generic health related QoL measure consisting of 26 items divided into 6 sub-scales.	baseline day 0, week 12
Improvement of Quality of Life by SF-36	The 36-Item Short Form Survey (SF-36) is an outcome measure instrument that comprises 36 questions that cover eight domains of health.	baseline day 0, week 12
Improvement of Quality of Life by Chalder Fatigue Scale (CFQ 11)	Change of Chalder Fatigue Scale (CFQ 11), with range from 0 to 11 (the bigger the score, the more fatigue a person feels), from baseline to week 12. The Chalder fatigue scale (CFQ 11) is a questionnaire created by the research team of Trudie Chalder at King's College London to measure the severity of tiredness in fatiguing illnesses.	baseline day 0, week 12
Change of SFQ from baseline	The change of frequency of sports activity by SFQ (Sports Frequency Questionnaire) from baseline to week 12	baseline day 0, week 12

Collaborators and Investigators

• Sponsor: Amway (China) R&D Center
• Investigators: Principal Investigator: Zhenzhong Lu, MD, Jinhua Wenrong Hospital

Study record dates

Study Major Dates

• Study Start (Actual): July 8, 2025
• Primary Completion (Actual): October 2, 2025
• Study Completion (Actual): October 2, 2025

Study Registration Dates

• First Submitted: July 6, 2024
• First Submitted That Met QC Criteria: July 6, 2024
• First Posted (Actual): July 12, 2024

Study Record Updates

• Last Update Posted (Actual): November 24, 2025
• Last Update Submitted That Met QC Criteria: November 19, 2025
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Keywords: WOMAC; SF-36; SPPB; Amway Nutrilite; All-plant Protein Booster; WHOQOL BREF; CFQ 11; SFQ
• Additional Relevant MeSH Terms: Neurologic Manifestations; Musculoskeletal Diseases; Nervous System Diseases; Neuromuscular Manifestations; Pathological Conditions, Anatomical; Arthritis; Joint Diseases; Rheumatic Diseases; Muscular Atrophy; Atrophy; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Osteoarthritis; Sarcopenia
• Other Study ID Numbers: IS20220021RD

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No